Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2026-A00712-49 | Other Identifier | ANSM |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| SMR Nutrition Obésité UGECAM | UNKNOWN |
| Laboratoire AME2P | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
The primary objective of this study is to investigate the effects of a multidisciplinary intervention, including a targeted adapted physical activity program, on lipid oxidation during a walking exercise in women with overweight or obesity, with or without polycystic ovary syndrome. Specifically, the study aims to compare changes in lipid oxidation before and after the intervention between women with polycystic ovary syndrome and those without polycystic ovary syndrome.
The secondary objectives are to assess the impact of polycystic ovary syndrome on several physiological and metabolic parameters in women with overweight or obesity. These include: (i) resting energy metabolism; (ii) resting blood pressure and heart rate; (iii) energy expenditure, energy cost, and heart rate during a walking exercise; (iv) body composition, glycemic and lipid profiles, and circulating levels of sex hormones and adipokines; (v) movement behaviors; and (vi) physical fitness.
In addition, the effect of the multidisciplinary intervention, including the adapted physical activity program, will be evaluated on these same outcomes: (i) resting energy metabolism; (ii) resting blood pressure and heart rate; (iii) energy expenditure, energy cost, and heart rate during walking exercise; (iv) body composition, glycemic and lipid profiles, and concentrations of sex hormones and adipokines; (v) movement behaviors; and (vi) physical fitness, in women with overweight or obesity, with or without polycystic ovary syndrome.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Physical activity intervention | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Physical activity | Behavioral | Participants will participate to adapted physical activity, supervised by a professional |
|
| Measure | Description | Time Frame |
|---|---|---|
| Lipid oxidation during walking exercise | Baseline and after 10 weeks of intervention |
| Measure | Description | Time Frame |
|---|---|---|
| Energy expenditure at rest | Baseline and after 10 weeks of intervention | |
| Lipid oxidation at rest | Baseline and after 10 weeks of intervention | |
| Carbohydrate oxidation at rest |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Lise Laclautre | Contact | +33473754963 | promo_interne_drci@chu-clermontferrand.fr |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHU de Clermont-Ferrand | Clermont-Ferrand | 63000 | France |
Internal regulation
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D050177 | Overweight |
| D009765 | Obesity |
| D011085 | Polycystic Ovary Syndrome |
| D009043 | Motor Activity |
| ID | Term |
|---|---|
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D009750 | Nutritional and Metabolic Diseases |
| D001835 | Body Weight |
Not provided
Not provided
| ID | Term |
|---|---|
| D015444 | Exercise |
| ID | Term |
|---|---|
| D009043 | Motor Activity |
| D009068 | Movement |
| D009142 | Musculoskeletal Physiological Phenomena |
| D055687 | Musculoskeletal and Neural Physiological Phenomena |
Not provided
Not provided
The participants will have different conditions, with or without polycystic ovary syndrome, but will follow the same intervention
Not provided
Not provided
Not provided
Not provided
| Baseline and after 10 weeks of intervention |
| Systolic blood pressure at rest | Baseline and after 10 weeks of intervention |
| Diastolic blood pressure at rest | Baseline and after 10 weeks of intervention |
| Heart rate at rest | Baseline and after 10 weeks of intervention |
| Energy expenditure during walking exercise | Baseline and after 10 weeks of intervention |
| Energy cost of walking | Baseline and after 10 weeks of intervention |
| Carbohydrate oxidation during walking exercise | Baseline and after 10 weeks of intervention |
| Heart rate during walking exercise | Baseline and after 10 weeks of intervention |
| Fat mass | Baseline and after 10 weeks of intervention |
| Fat-free mass | Baseline and after 10 weeks of intervention |
| Body hydration | Baseline and after 10 weeks of intervention |
| Fasting glycemia | Baseline and after 10 weeks of intervention |
| Fasting insulin concentrations | Baseline and after 10 weeks of intervention |
| Fasting triglyceride concentrations | Baseline and after 10 weeks of intervention |
| Fasting LDL cholesterol concentrations | Baseline and after 10 weeks of intervention |
| Fasting HDL concentrations | Baseline and after 10 weeks of intervention |
| Fasting total cholesterol concentrations | Baseline and after 10 weeks of intervention |
| Fasting free-fatty acid concentrations | Baseline and after 10 weeks of intervention |
| Follicle-stimulating hormone concentrations | Baseline and after 10 weeks of intervention |
| Luteinizing hormone concentrations | Baseline and after 10 weeks of intervention |
| Estrogen concentrations | Baseline and after 10 weeks of intervention |
| Progesterone concentrations | Baseline and after 10 weeks of intervention |
| Total testosterone concentrations | Baseline and after 10 weeks of intervention |
| Free testosterone concentrations | Baseline and after 10 weeks of intervention |
| Fasting leptin concentrations | Baseline and after 10 weeks of intervention |
| Fasting adiponectin concentrations | Baseline and after 10 weeks of intervention |
| Time spent in sedentary behaviors | Baseline and after 10 weeks of intervention |
| Time spent in moderate-to-vigorous physical activity | Baseline and after 10 weeks of intervention |
| Physical fitness-minute walking distance | Baseline and after 10 weeks of intervention |
| Right hand grip strength | Baseline and after 10 weeks of intervention |
| Left hand grip strength | Baseline and after 10 weeks of intervention |
| Number of repetitions during the 30-seconde chair stand test | Baseline and after 10 weeks of intervention |
| Herat rate at the end of the step test | Baseline and after 10 weeks of intervention |
| Heart rate 1 minute after the end of the step test | Baseline and after 10 weeks of intervention |
| Heart rate 2 minutes after the end of the step test | Baseline and after 10 weeks of intervention |
| Heart rate 3 minutes at the end of the step test | Baseline and after 10 weeks of intervention |
| D012816 |
| Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D010048 | Ovarian Cysts |
| D003560 | Cysts |
| D009369 | Neoplasms |
| D010049 | Ovarian Diseases |
| D000291 | Adnexal Diseases |
| D005831 | Genital Diseases, Female |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D000091662 | Genital Diseases |
| D006058 | Gonadal Disorders |
| D004700 | Endocrine System Diseases |
| D001519 | Behavior |